Racial differences in the association of CD14 polymorphisms with serum total IgE levels and allergen skin test reactivity.
Date
2013-01
Journal Title
Journal ISSN
Volume Title
Repository Usage Stats
views
downloads
Citation Stats
Attention Stats
Abstract
BACKGROUND: The CD14 C-159T single nucleotide polymorphism (SNP) has been investigated widely as a candidate genetic locus in patients with allergic disease. There are conflicting results for the association of the CD14 C-159T SNP with total serum immunoglobulin E (IgE) levels and atopy. There are limited data regarding the association of the CD14 C-159T SNP in subjects of African ancestry. The aim of the study was to determine whether the C-159T SNP and other CD14 SNPs (C1188G, C1341T) were associated with total serum IgE levels and with allergy skin test results in nonatopic and atopic subjects; as well as in Caucasian and African American subjects. METHODS: A total of 291 participants, 18-40 years old, were screened to determine whether they were atopic and/or asthmatic. Analyses were performed to determine the association between CD14 C-159T, C1188G, or C1341T genotypes with serum IgE levels and with the number of positive skin tests among Caucasian or African American subjects. RESULTS: We found no significant association of serum total IgE level with CD14 C-159T, C1188G, or C1341T genotypes within nonatopic or atopic subjects. Subjects with CD14-159 T alleles had significantly more positive allergen skin tests than subjects without CD14-159 T alleles (P = 0.0388). There was a significant association between the CD14 1188 G allele, but not the CD14 1341 T allele, with the number of positive skin-test results in Caucasians, but not in African Americans. CONCLUSION: These results support a possible association between CD14 polymorphisms and atopy. CD14-159 T or CD14 1188 G alleles were associated with atopic disease. For subjects with CD14 1188 G alleles, the association with atopic disease was stronger in Caucasians compared to African Americans.
Type
Department
Description
Provenance
Subjects
Citation
Permalink
Published Version (Please cite this version)
Publication Info
Wang, Zongyao, John S Sundy, Catherine M Foss, Huiman X Barnhart, Scott M Palmer, Sallie D Allgood, Evan Trudeau, Katie M Alexander, et al. (2013). Racial differences in the association of CD14 polymorphisms with serum total IgE levels and allergen skin test reactivity. Journal of asthma and allergy, 6. pp. 81–92. 10.2147/jaa.s42695 Retrieved from https://hdl.handle.net/10161/21126.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
Collections
Scholars@Duke
John Sargent Sundy
Research Theme
The focus of my research is on human-based translational studies and therapeutic trials of novel agents for inflammatory and immunologic diseases. My group has experience in mechanistic studies of environmental exposure in airway diseases; genetic analysis and gene expression studies using microarrays; airway challenge and assessment of response in the upper and lower airway and periphery; and therapeutic trials of experimental agents in Phases I-IV. Areas of focus include:
Asthma and Allergic Diseases
Research interests in asthma and allergic diseases focus upon human studies investigating the response to environmental endotoxin exposure. Using airway challenge with lipopolysaccharide and well characterized allergens, we investigate the genetic regulation of immunologic and inflammatory responses in the lung and in the periphery. This work is performed in collaboration with investigators with expertise in bench science and computational biology. In addition I participate in a number of multi-center research projects related to experimental therapeutics and genetic susceptibility to asthma and allergic diseases.
Rheumatologic Diseases
My primary research focus in rheumatologic diseases is on experimental therapeutics in chronic gout. Gout is the most common inflammatory arthritis in men, and the prevalence of disease is increasing in the population. We have led Phase I through III studies of pegloticase (PEGylated uricase) in subjects with treatment failure gout. We have initiated a new line of investigation that focuses upon IL-1 inhibition in the treatment of inflammation in acute and chronic gout.
Duke Clinical Research Institute - Multicenter Clinical Trials
I serve as the Director of Rheumatology and Allergy Research at the Duke Clinical Research Institute, a large academic research organization with expertise in the coordination of multi-center clinical trials and registries. Our objective is to develop a diverse portfolio of research registries and clinical trials in rheumatic and immunologic disease led by investigators at Duke. Currently our group is involved in programs in pediatric lupus, systemic onset JIA, gout, rheumatoid arthritis, and scleroderma.
Huiman Xie Barnhart
My research interests include both statistical methodology and disease-specific clinical research biostatistics. My statistical research areas include methods for outcomes, endpoints, estimands, assessing reliability/agreement between methods or raters, evaluating performance of new medical diagnostic tests, and methods for design of clinical trials. My collaborative research include the following clinical areas: liver injury, cardiovascular imaging, radiology imaging, cardiovascular disease, renal disease, reproductive medicine, Parkinson disease, and aging.
Scott Michael Palmer
Dr. Palmer is a physician investigator, clinician, and academic leader. He is a Donald F. Fortin, MD Distinguished Professor of Medicine at Duke University, Vice Chair for Research in the Department of Medicine, Director of Medicine Plus Therapeutic Area at the Duke Clinical Research Institute, and Director of Clinical Research in the Duke Transplant Center. He is an expert in the care of patients with advanced lung diseases, such as interstitial lung diseases (ILDs), chronic obstructive pulmonary disease (COPD), and lung transplantation.
Dr. Palmer’s successful research career includes over 20 years of continuous NIH funding and over 300 publications. He has held key leadership roles in national and international pulmonary and transplant societies, has chaired many sessions at national and international meetings, served on the editorial board for prominent journals, and serves regularly on grant review study sections. He has received numerous honors including election into Alpha Omega Alpha (AOA), the American Society for Clinical Investigation (ASCI), and the Association of American Physicians (AAP).
During his career, he has led numerous multicenter clinical trials, data coordinating centers, registries and large real-world data studies across different lung diseases. His research in lung diseases has defined the best clinical practices, discovered novel biomarkers, and identified genetic risk factors. His work in idiopathic pulmonary fibrosis (IPF) advanced the clinical development of LPA1 antagonism as a treatment. His work in bronchiolitis obliterans syndrome (BOS) identified immune mechanisms that alter airway cell biology and underly disease development. He continues to lead multicenter studies that generate high quality evidence to guide patient care and to utilize cutting edge translational approaches such as single cell and spatial transcriptomics of human lung tissue to discover lung disease mechanisms.
Dr. Palmer is a dedicated mentor to trainees and junior faculty, having personally mentored over 40 pre- and post-doctoral trainees, many of whom are now engaged in their own successful research careers. He also co-leads multiple institutional training programs, including R38 and T32 grants, reflecting his deep commitment to training the next generation of academic investigators.
Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.